Stockreport

Leveragen Announces Collaboration with Daiichi Sankyo to Support Development of Advanced Biologics Using Next-Gen In Vivo Antibody Discovery Platforms [Yahoo! Finance]

DAIICHI SANKYO S/ADR  (DSNKY) 
PDF in vivo antibody discovery capabilities in support of selected research programs. The collaboration reflects a shared interest in exploring innovative discovery approach [Read more]